Results 1 to 10 of about 35,895 (269)

PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy [PDF]

Journal of Hematology & Oncology
Background Consolidation durvalumab following no progression on concurrent chemoradiotherapy (cCRT) is standard of care for unresectable stage III non-small-cell lung cancer (NSCLC).
Yi-Long Wu, Lin Wu, Nan Bi, Timucin Cil, Hong Ge, Zhengfei Zhu, Chih-Liang Wang, Wei Zhang, Dongqing Lv, E. Mingyan, Jianguo Sun, Yi Pan, Maciej Krzakowski, Mustafa Dikilitas, Mehmet Ali Nahit Sendur, Young-Chul Kim, Yanjiao Yang, Rui Mao, Biao Zhang, Luhua Wang   +19 more
doaj   +2 more sources

Development of Clinical-Grade Durvalumab-680LT and Nivolumab-800CW for Multispectral Fluorescent Imaging of the PD-1/PD-L1 Axis of the Immune Checkpoint Pathway [PDF]

Pharmaceuticals
Background: Immune checkpoint inhibitors (ICIs) are effective against various advanced and metastatic cancers, but patient responses vary and can change over time, complicating treatment prediction.
Henrik K. Huizinga, Wouter T. R. Hooghiemstra, Matthijs D. Linssen, Derk P. Allersma, Bahez Gareb, Bart G. J. Dekkers, Wouter B. Nagengast, Marjolijn N. Lub-de Hooge   +7 more
doaj   +2 more sources

Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial [PDF]

Nature Medicine
Benjamin Besse, Sylvia Hartl, Melissa L Johnson   +2 more
exaly   +2 more sources

Association Between the Early Discontinuation of Durvalumab and Poor Survival in Patients With Stage III NSCLC

JTO Clinical and Research Reports, 2021
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unknown ...
Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD   +6 more
doaj   +1 more source

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Clinical and Translational Radiation Oncology, 2023
Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended.
Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri   +5 more
doaj   +1 more source

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer

Thoracic Cancer, 2022
Background Durvalumab consolidation is associated with improved survival following concurrent chemoradiotherapy (CCRT) in patients with stage III non‐small cell lung cancer (NSCLC).
Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Alvin Wong, Folefac Aminkeng, Yvonne Ang, Yugarajah Asokumaran, Jia Li Low, Matilda Lee, Joan R. E. Choo, Gloria Chan, Adrian Kee, Sen Hee Tay, Boon Cher Goh, Ross A. Soo   +14 more
doaj   +1 more source

Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma

Scientific Reports, 2021
This study sought to understand how the programmed death ligand 1 (PD-L1) inhibitor durvalumab and the immunomodulatory agent pomalidomide regulate immune cell activation and function in patients with relapsed/refractory (RR) multiple myeloma (MM ...
Mary H. Young, Greg Pietz, Elizabeth Whalen, Wilbert Copeland, Ethan Thompson, Brian A. Fox, Kathryn J. Newhall   +6 more
doaj   +1 more source

Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial

Cost Effectiveness and Resource Allocation, 2023
Background Durvalumab plus gemcitabine and cisplatin has a significant clinical benefit for advanced biliary tract cancer (BTC). However, the high price of durvalumab warrants an exploration of the economics.
Qiuling Zhao, Ruixiang Xie, Wanfu Zhong, Wenbin Liu, Ting Chen, Xiuliang Qiu, Lin Yang   +6 more
doaj   +1 more source

Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial

Cancer Reports, 2023
Background Studies suggest that immune checkpoint inhibitors may represent a promising strategy for boosting immune responses and improving the antitumor activity of standard therapies in patients with relapsed/refractory hematologic malignancies.
Carla Casulo, Armando Santoro, Guillaume Cartron, Kiyoshi Ando, Javier Munoz, Steven Le Gouill, Koji Izutsu, Simon Rule, Pieternella Lugtenburg, Jia Ruan, Luca Arcaini, Marie‐Laure Casadebaig, Brian Fox, Nurgul Kilavuz, Nils Rettby, Justine Dell'Aringa, Lilia Taningco, Richard Delarue, Myron Czuczman, Thomas Witzig   +19 more
doaj   +1 more source

Chemoradiation followed by adjuvant durvalumab in stage III non–small cell lung cancer: Real‐world comparison of treatment outcomes to historical controls treated with chemoradiation alone

Thoracic Cancer, 2022
Objective Compare outcomes in patients with stage III non–small cell lung cancer (NSCLC) treated with chemoradiation and adjuvant durvalumab to historical controls treated with chemoradiation alone.
Akram Saad, Jeffrey Goldstein, Sarit Appel, Sameh Daher, Damien Urban, Amir Onn, Hadas Gantz‐Sorotsky, Anastasiya Lobachov, Teodor Gottfried, Benjamin Spieler, Jair Bar   +10 more
doaj   +1 more source